Pharma BD Deal Intelligence
GSK joins chase for hot cancer target TIGIT, paying iTeos $625M upfront in new alliance for EOS-448 anti-TIGIT antibody.
GSK and iTeos discontinuing belrestotug after phase 2 GALAXIES Lung-201 and H&N-202 interim analyses did not meet efficacy criteria; the collaboration and all…
iTeos announces corporate wind-down following termination of the GSK belrestotug collaboration; severance and program/clinical wind-down charges disclosed.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
In June 2021 GSK paid iTeos Therapeutics $625M upfront (deal value up to ~$2.075B with $550M development/regulatory and $900M commercial milestones, plus equal US profit share and ex-US royalties) to co-develop and co-commercialize belrestotug (EOS-448), an Fc-active anti-TIGIT monoclonal antibody, for next-generation immuno-oncology combinations. On 13 May 2025 GSK and iTeos terminated the belrestotug program and ended the collaboration after the Phase 2 GALAXIES Lung-201 interim analysis (belrestotug + dostarlimab in first-line PD-L1-high NSCLC) failed to show clinically meaningful progression-free survival despite an improved objective response rate, and the GALAXIES H&N-202 head-and-neck cohort trended below the ORR threshold. All belrestotug-containing cohorts ended and new enrollment in the Phase 3 GALAXIES Lung-301 trial stopped; iTeos subsequently announced a corporate wind-down. The deal joins a long list of TIGIT-class clinical failures, with GSK's $625M upfront unrecovered.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / iTeos Therapeutics S.A. (this deal) | 2021 | $2.1B | 28 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2021 deals · GlaxoSmithKline plc deals · Oncology deals